The historical rank and industry rank for BeOne Medicines's OCF Margin % or its related term are showing as below:
BSP:B1ME34'
s OCF Margin % Range Over the Past 10 Years
Min: -8365.7 Med: -108.06 Max: 21.1
Current: 22.45
During the past 13 years, the highest OCF Margin % of BeOne Medicines was 21.10%. The lowest was -8365.70%. And the median was -108.06%.
BSP:B1ME34's OCF Margin % is ranked better than 85.1% of 960
companies
in the Biotechnology industry
Industry Median: -68.59
vs BSP:B1ME34: 22.45
BeOne Medicines OCF Margin % Related Terms
BeOne Medicines OCF Margin % Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:B1ME34 vs RVMD, RPRX, BNTX: OCF Margin % Comparison
For the Biotechnology subindustry, BeOne Medicines's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's OCF Margin % distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (BSP:B1ME34) has a OCF Margin % of 13.30% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #143 out of 960 companies in the Biotechnology industry, placing it in the top 14.9%.
Is BeOne Medicines' OCF Margin % too high?
BeOne Medicines' current OCF Margin % is 13.30%. Based on the distribution chart, BeOne Medicines ranks #143 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' OCF Margin % compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #143 out of 960 companies for OCF Margin %. This places BeOne Medicines in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current OCF Margin % is 13.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (BSP:B1ME34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$74.21, compared to a current price of R$56.20 — trading 24.3% below its estimated fair value. The current OCF Margin % is 13.30%. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BeOne Medicines (BSP:B1ME34), the current OCF Margin % is 13.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (BSP:B1ME34) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of R$56.20 is trading 24.3% below its estimated GF Value™ of R$74.21.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for BSP:B1ME34:
OCF Margin %: 13.30%
GF Value™: R$74.21 vs. price of R$56.20 (24.3% below fair value)
No single metric tells the full story. See the BSP:B1ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for BSP:B1ME34
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1ME34 has been successfully added to your 
